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Aim To assess diseases outcomes and tolerability of real-
life second-line nivolumab in a series of metastatic renal 
cell carcinoma (mRCC) patients.
Methods This retrospective chart review involved pro-
spectively monitored patients (named patient program) 
treated with second-line nivolumab for mRCC at the Uni-
versity Hospital Centre Zagreb from February 2016 to 
March 2018.
Results The study enrolled 30 patients, 5 of whom (16.7%) 
had a complete response. The mean ± standard deviation 
therapeutic response time to nivolumab treatment was 
14.07 ± 8.92 months, with a minimum treatment duration 
of 2 months and a maximum of 24 months. The median 
duration of therapy was 17 months (mean: 15.8 months; 
range: 3-24 months), and 50% (n = 15/30) of patients re-
mained alive at the end of follow up. The most common 
adverse events associated with nivolumab were fatigue 
(26.67%; n = 8/30), anemia (10.0%; n = 3/30), adrenal insuffi-
ciency (6.67%; n = 2/30: G1 = 1, G2 = 1), grade 2 pneumoni-
tis (6.67%; n = 2/30), grade 2 neuropathy (6.67%; n = 2/30), 
rash (6.67%; n = 2/30: G1 = 1, G2 = 1), and hepatitis (3.33%; 
n = 1/30).
Conclusion The present study indicates acceptable pa-
tient responses and tolerability of nivolumab in mRCC.
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Each year, approximately 337 000 new cases of renal cell 
carcinoma (RCC) are diagnosed globally, with 143 000 
deaths (1). Thirty-three percent of the patients who un-
dergo surgical intervention relapse and additional 33% 
develop metastases upon initial diagnosis (2,3). A total of 
75%-85% of primary kidney malignancies belong to the 
group of clear cell RCCs, while the remaining histologically 
diverse tumors are categorized as non-clear cell RCC. Non-
clear cell RCCs differ from clear cell RCCs in pathologic and 
histologic features and clinical presentation (3). Early diag-
nosis of RCC is crucial as timely surgical intervention can 
prolong the patient’s life (5-year survival rate of 93%). Un-
fortunately, a third of the patients already have advanced 
disease at diagnosis and 10%-20% of them experience a 
relapse (4-7).
Over the past few years, RCC has been successfully treat-
ed with endothelial growth factor receptor tyrosine kinase 
(VEGF TKI) and mammalian target of rapamycin inhibitors 
(mTORi) (8). VEGF TKIs are highly effective and can safely 
be used for several years. However, the median overall sur-
vival (22-29 months) suggests that there is still room for 
improvement (9). Therefore, it is paramount that clinicians 
have an expert understanding of immunotherapy, as most 
patients with advanced RCC undergo multiple therapies 
over the course of their disease (10).
Nivolumab is a PD-1 checkpoint inhibitor that restores the 
pre-existing antitumor immune response by selectively 
blocking the interaction between PD-1 receptors on T-cells 
and PD-1 ligands, PD-L1 and PD-L2, on tumor cells and an-
tigen presenting cells. A 2012 phase I trial demonstrated 
nivolumab’s antitumor activity and manageable safety 
profile in metastatic RCC (11). In 2015, nivolumab was ap-
proved (CheckMate 025) by Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA) as a 
second-line therapy for advanced RCC patients with prior 
anti-angiogenic therapy, and in 2018 by the EMA as the 
first-line therapy for patients with intermediate- and poor-
risk advanced RCC (12,13).
Since approval, a number of clinical trials have been con-
ducted to further assess the safety, tolerability, and efficacy 
of nivolumab, or the combination of nivolumab with an-
other antitumor therapeutic agent, in RCC treatment (14-
16). We aimed to assess disease outcomes and tolerability 
of real-life second-line nivolumab in a series of mRCC pa-
tients. Our primary aim was to evaluate the dose response 
with regards to progression-free survival (PFS), overall sur-
vival (OS), and time-to-treatment failure (TTF). The second-
ary aim was to assess the relative safety of nivolumab as 
a second-line therapy by assessing nivolumab-related ad-
verse events.
PAtiENts AND MEthoDs
In February 2019, we retrospectively reviewed the charts 
of patients with an indication for treatment with nivolum-
ab for mRCC managed between February 2016 and March 
2018 at the Clinical Hospital Centre Zagreb. Patients were 
identified through the Center’s electronic health record 
database, and all patients who received nivolumab were 
included. Patient data were collected in compliance with 
all ethical and regulatory standards regarding patient con-
fidentiality.
The study recruited all patients who took part in a named 
patient program according to the EMA’s medication reg-
istration criteria. Heng and MSKCC/Motzer score models 
for predicting survival were used as inclusion criteria and 
for stratification of patients into a favorable-risk group, 
intermediate-risk group, and poor-risk group. Treatment 
duration was defined as the period from the initial treat-
ment start date to the date of the last treatment cycle. 
Response to therapy was defined as either complete re-
sponse (CR), partial response (PR), stable disease (SD), or 
progressive disease (PD) according to RECIST (17). Patients 
in whom it was impossible to determine whether they 
had progression, regression, or stable disease were classi-
fied as “mixed response” patients (“modified RECIST”). The 
PFS was defined as the time in months between the initia-
tion of therapy to progression of disease or death, where-
as OS was defined as the time in months from the initi-
ation of therapy to death. Time-to-treatment failure was 
defined as the interval from the initiation of therapy to its 
premature discontinuation, which could have ensued due 
to different reasons, such as cancer progression, adverse 
events, patient choice, or patient death. The patients were 
re-assessed at regular scheduled visits at 2, 3, 6, 9, 12, 15, 
18, and 24 months.
Nivolumab was administered at a standard dose of 3 mg/
kg every two weeks for up to two years. Patients were 
asked to visit their oncologist every three months for con-
trol and consultation. The follow-up visits included labo-
ratory tests, multi-slice computed tomography (MSCT) of 
the chest, abdomen, and pelvis, and bone status. Patients 
with musculoskeletal pain underwent a bone scan. The 
treatment duration ranged from 3 months (shortest) to 
24 months (longest).
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therapy ECoG smoking Alcohol
1 M 62 L, M, bones Y CC, pT3aN0M1 DP  7 Fatigue G2, rash G1 sunitinib 50 mg 2 N-ES N
2 M 58 L, parotid 
gland
Y CC, pT2N1M1 CR 24 sunitinib 50 mg 0 Y Y
3 F 53 bones Y Papillary, 
pT3N2M0
DP  6 Fatigue G2, anemia G2, 





4 F 73 bones Y CC, pT1bN0M1 SD 22+ sunitinib 50 mg 0 N N
5 M 63 L, M Y CC DP 22+ sunitinib 50 mg 1 N N
6 F 61 LN,M, pan-
creas
N CC SD  8 Hypothyreosis G2, 
adrenal insufficiency G2, 
hepatitis G4
sunitinib 50 mg 1 N N
7 M 72 bones Y CC, T1 Mix  8 sunitinib 50 mg 3 N-ES N
8 F 71 L, bones Y CC, pT3N0M0 DP  9 sunitinib 50 mg 3 N N
9 M 68 L, adrenal 
gland, M
Y CC, pT3aNxM1 SD 20+ Fatigue G2, hypophysitis 
G2, adrenal insufficiency 
G1
sunitinib 50 mg 0 N N
10 M 68 bones, LN Y Papillary type2, 
pT3a
DP 10 temsirolimus 
25 mg
2 N-ES N
11 F 77 bones Y CC, pT2aNxM1 DP 10 sunitinib 50 mg 3 N N
12 F 66 L Y CC, pT3bN0M0 DP  8 sunitinib 50 mg 3 N N
13 M 38 M, bones, L Y CC, pT1bN0M0 PR 19+ Fatigue G2, anemia G2, 
pneumonitis G2
sunitinib 50 mg 1 N N
14 M 75 L, forearm Y CC, M1 SD 19+ pazopanib 800 
mg
0 N N
15 M 67 L Y CC, pT3aN0M0 SD 19+ sunitinib 50 mg 0 N N
16 M 65 L, bones, ad-
renal gland, 
kidney
N CC, M1 DP  4 sunitinib 50 mg 3 N N
17 M 68 L Y CC, pT2bNxM0 SD  9 CVI sunitinib 50 mg 2 N-ES N





DP  5 Anemia G2, fatigue G3 sunitinib 50 mg 3 N-ES N
19 M 82 LN,M Y CC, pT3bNxMx SD 10 Pneumonitis G2, neu-
ropathy G2, myasthenia 
syndrome G1
votrient 800 mg 3 N-ES N
20 M 86 prostatic 
urethra
Y CC, N0 DP  7 sunitinib 50 mg 3 N N
21 F 84 L, M, LN Y CC,M1 CR 15+ votrient 800 mg 1 N N
22 M 65 L Y CC SD  9 Fatigue G1, colitis first 
G3 subsequently G4
votrient 800 mg 1 N N
23 M 60 bones, M, 
peritoenum, 
L, LN
Y CC, pT2N0M1 DP  3 sunitinib 50 mg 3 N-ES N
24 M 59 bones, L, N CC DP  5 sunitinib50 mg 3 N N
25 M 56 bones Y CC, pT2N0Mx DP 14+ sunitinib 50 mg 0 N N
26 M 63 L Y CC, M1 SD 15+ Fatigue G1, nephritis G2 votrient 800 mg 3 N N
27 F 81 L Y CC, pT2N0M1 DP 16+ Uveitis G2 sunitinib50 mg 0 N N
28 M 66 LN, adrenal 
gland
Y CC, pT3N0M0 CR 20+ Fatigue G2 sunitinib50 mg 0 N N
29 M 68 M, LN, mes-
enteri
Y CC, T3bN2M1 SD 20+ sunitinib 50 mg 0 N N
30 M 59 LN, M, L, 
bones, liver
Y CC, pT2N0Mx DP  3 sunitinib 50 mg 3 N N
*L – lungs; M – mediastinal lymph nodes; LN – abdominal lymph nodes; CC – clear cell cancer; sD – stable disease; DP – disease progression; PR – partial response; CR – 
complete response; MiX – combination PR/sD/DP; Y – yes; N – no; N-Es – no-ex smoker; PhD – pathohistology diagnosis; tNM – tumor-node-metastases.
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All relevant data were collected during treatment and 
were used to determine the baseline characteristics and 
adverse events observed during nivolumab therapy. De-
scriptive statistical analysis was performed using the R pro-
gramming language, v.3.4.0 (The R Foundation for Statisti-
cal Computing, Vienna, Austria) to evaluate the differences 
in patients’ safety and therapeutic response to nivolumab.
REsuLts
Patients’ characteristics
The study involved 30 patients (73% men). The mean age 
at diagnosis was 60.2 ± 9.72 years, ranging from 33 to 78 
years (Table 1). There were 70.67% non-smokers (n = 21/30), 
23.33% ex-smokers (n = 7/30), and 6.67% smokers (n = 2/30). 
A total of 3.33% reported alcohol consumption (n = 1/30). 
The number of metastatic sites before the first-line ther-
apy ranged from 1 to 5 (50.0% to 3.33%) and metastatic 
sites were found in various tissues and organs, including 
the lymph nodes (39.62%; n = 21/30), lymph node medi-
astinum (18.87%; n = 10/30), bones (16.98%; n = 9/30), ad-
renal glands (7.55%; n = 4/30), and parotid gland and peri-
toneum (1.89%; n = 1/30 in each).
Before nivolumab therapy, 90% of patients (n = 27/30) had 
undergone nephrectomy and had received three types of 
therapy: 50 mg of sunitinib for 4 weeks:2 weeks/2 weeks:1 
week (77%; n = 23/30), 800 mg of continuous pazopanib 
(17%; n = 5/20), and 2 5mg of temsirolimus weekly (6%; 
n = 2/30). The Eastern Cooperative Oncology Group (ECOG) 
score at the start of therapy was 0 in 56.67% (n = 17/30), 1 
in 36.67% (n = 11/30), and 2 in 6.67% (n = 2/30) of patients 
(Table 1).
therapeutic response
The mean ± standard deviation response time to nivolum-
ab treatment was 14.07 ± 8.92 months, with a minimum re-
sponse time of 2 months and a maximum of 24 months. 
The median duration of therapy was 17 months (mean: 15.8 
months; range: 3-24 months). The therapeutic response 
(stable disease-partial response-complete response, dis-
ease progression) is shown in Figure 1 and OS, PFS, and 
TTF in Figure 2. Patients who were treated with nivolum-
ab for 6 to 12 months, in spite of radiological progression, 
were ECOG 0-1 and were still alive at the last follow-up vis-
it, while 5 out of 30 (16.7%) had a complete response. At 
12 months of follow up, OS was 90% (n = 27/30), PFS 43% 
(n = 13/30), and TTF 53% (n = 16/30). At 24 months, OS was 
still not reached as 50% (n = 15/30) of the patients were 
alive at the last follow-up visit, TTF was 50% (n = 15/30), and 
PFS remained 43% (n = 13/30) (Figure 2).
safety
The follow-up period for adverse events was 25 months. 
The most common adverse event was fatigue (26.67%; 
n = 8/30), followed by anemia (10.0%; n = 3/30), adrenal in-
sufficiency (6.67%; n = 2/30: G1 = 1, G2 = 1), grade 2 pneu-
monitis (6.67%; n = 2/30), grade 2 neuropathy (6.67%; 
n = 2/30), rash (6.67%; n = 2/30: G1 = 1, G2 = 1), and hepati-
tis (3.33%; n = 1/30). Patients who developed grade 1 and 
FiGuRE 1. Duration of nivolumab therapy and patient 
response over the course of treatment. sD – stable disease; 
DP – disease progression; PR – partial response; CR – complete 
response; MiX – combination PR/sD/DP.
FiGuRE 2. overall survival (os), progression free survival 
(PFs), and time to treatment failure (ttF) curves of 30 patients 
treated with nivolumab for metastatic renal cell carcinoma.
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grade 2 adrenal insufficiency, grade 2 nephropathy, grade 
2 hypothyroidism, and pneumonitis were successfully 
managed by the attending physician. After we excluded 
RCC spread leading to adrenal insufficiency and differen-
tiated an infection from pneumonitis by imaging studies, 
adverse events were treated with corticosteroids (predni-
sone 1 to 2 mg/kg per day or methylprednisolone i.v. 1 to 
2 mg/kg per day with dose tapering over 4 weeks). In the 
case of endocrine toxicity, gland specific hormones were 
added to corticosteroid regimen. Patients with hepatitis 
G3 or G4 were not administered mycophenolate mofetil, 
since toxicity started to decrease three days after nivolum-
ab was discontinued. Nivolumab therapy was also stopped 
in a patient with colitis G4, and toxicity disappeared fol-
lowing corticosteroid treatment (prednisone 2 mg/kg/d) 
(Table 1 and Figure 3).
DisCussioN
Our findings show acceptable patient response and man-
ageable safety profile of nivolumab for RCC, which is con-
sistent with the drug’s recent approvals in this indication 
by the regulatory agencies. The incidences of immune re-
lated adverse events in this study were comparable with 
those described in the literature (18,19). Furthermore, niv-
olumab with its mean duration of treatment of 14.07 ± 8.92 
months appears to be a good second-line therapy option 
for patients who also had a long response (>1 year) time to 
TKI in the first line therapy.
In the last few years advanced RCC has been success-
fully treated by combinations of immunooncologic 
therapies. However, the optimal drug sequential therapy 
for every patient remains to be found. The outcome of 
mRCC has improved with the advancement of targeted 
therapies (20). There are seven targeted therapies currently 
available for clear cell RCC: VEGFR TKIs (sorafenib, sunitinib, 
pazopanib, and axitinib); VEGF-directed monoclonal anti-
body bevacizumab (approved in combination with IFN); 
and mTORi (everolimus and temsirolimus). Although these 
agents achieved a positive impact, long-term responders 
are rare (21). High-dose IL-2 is the only approved agent to 
produce complete durable responses, but hospitalization 
and intense monitoring are still required (22).
In one of the first trials with nivolumab on 236 patients 
who received the drug every two weeks (0.1-10 mg/kg), re-
sponses were identified in NSCLC (18%), melanoma (28%), 
and RCC (27%), many of which were durable (10). Since the 
FDA’s and EMA’s approval of nivolumab as a second-line 
agent for therapy of advanced RCC, a number of clinical 
trials and studies have confirmed its effectiveness and safe-
ty in that indication (18,19,23,24). ChekMate 025 trial, con-
ducted during more than 5 years in metastatic clear cell 
RCC patients, found that nivolumab was a better treatment 
choice than everolimus, with a median OS of 25.8 months 
vs 19 months (25). Nivolumab also showed improved PFS.
The limitations of this study include a small study sample 
and potential information and selection bias. Additional-
ly, we did not use cabozantinib, as it is not reimbursed by 
the Croatian Health Insurance Fund. Despite such potential 
weaknesses, we believe that our results verify the current 
direction of investigations into the effectiveness and safety 
of nivolumab, thus reaffirming this drug’s potential to be-
come the standard treatment for patients with advanced 
RCC with prior antiangiogenic therapy (12,24). Since im-
munotherapy in the second-line treatment demonstrated 
good results in metastatic clear cell RCC patients, a com-
bination of immuno-immuno therapy (nivolumab/ipili-
mumab) or immuno (pembrolizumab or avelumab) and 
TKI (axitinib) therapy is increasingly being used as the first-
line treatment (26).
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